Skip to main content
OpenTrials
Completed

NCT Number: NCT01066572

Paramedic Initiated Lisinopril For Acute Stroke Treatment

This study aims to investigate the use of lisinopril to lower blood pressure in stroke patients, pre-hospital, by research-trained paramedics.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Wansbeck General Hospital, Ashington, Northumberland, United Kingdom

Loading trial locations.

About this study

High blood pressure immediately following stroke is common and related to poorer stroke functional outcome and death. Although treatment of high blood pressure is well established for thre prevention of stroke, it is unclear if high blood pressure observed immediately after stroke should be lowered.

Several previous clinical trials have lowered blood pressure in acute stroke but this has not resulted in improved stroke outcome. One reason for this may be because treatment was started too late after stroke occurred. There is rapid progression of brain injury following stroke and any stroke treatment may need to be started very early to have a beneficial effect. Previous trials started blood pressure lowering after patients arrived at hospital and this was usually a significant time after stroke occurred.

The earliest time after stroke that blood pressure treatment could be started is during contact with the emergency medical services (paramedics). This research study is a pilot double blind randomised controlled trial of paramedic initiated blood pressure treatment for patients with high blood pressure immediately after stroke.

Patients with high blood pressure and suspected acute stroke will be identified and offered the opportunity to participate in the study by research trained paramedics from the North East Ambulance Service NHS Trust. Patients who agree to participate in the study will receive either lisinopril (a common blood pressure lowering medication) or 'dummy' (placebo) treatments for seven days. The first dose of medication will be given by the paramedic in the ambulance. Subsequent tablets will be given in hospital. The effects of treatment will be monitored by measuring blood pressure, neurological outcome and adverse events.

All aspects of study feasibility including recruitment rates and compliance with data collection will be recorded. The study will run for one year and recruit 60 patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults ≥ 40 years old
  • New unilateral arm weakness thought to be due to acute stroke within 3 hours of symptom onset
  • Hypertension as defined by systolic BP >160mm Hg on two consecutive seated or lying readings taken 5 - 10 minutes apart
  • Conscious (eyes open spontaneously ie "A" on Alert, Voice, Pain, Unresponsive (AVPU) scale)
  • Patient being transported to a PIL-FAST trial site (i.e. Royal Victoria Infirmary, North Tyneside General Hospital and Wansbeck General Hospital)
  • Verbal consent obtained from participant or next of kin

Exclusion criteria

  • Age < 40 years
  • Females who are pregnant, lactating or at risk of pregnancy (i.e. who are not surgically sterile or at least 1 year post last menstrual period). Females < 56 years of age consented by a relative will be excluded as menstrual history may be unknown.
  • Any presentation of suspected stroke without unilateral arm weakness
  • Cannot establish that stroke onset time (i.e. when patient was last seen well without symptoms) was within the last 3 hours
  • Systolic BP < 160mm Hg
  • Reduced level of consciousness (below "A" on AVPU scale)
  • Patient not being transported to PIL-FAST trial site
  • Absence of participant or next of kin consent
  • Known to be taking ACE-inhibitor or Angiotensin II Receptor Blocker medication already
  • Known sensitivity to lisinopril or other ACE-inhibitor medication
  • Pulse > 120 beats per minute
  • Seizure activity in this illness episode (witnessed or history)
  • Hypoglycaemia (blood glucose < 3.5 mmols/l)
  • Cannot walk independently prior to stroke (walking stick / frame is allowed)
  • Obvious understanding or memory problems when next of kin is absent
  • Significant head trauma or brain surgery in the last 3 months
  • Known renal failure
  • Known liver failure (or currently jaundiced)
  • Uncontrolled heart failure (breathlessness at rest)
  • Receiving palliative care for known malignancy
  • Currently enrolled in a clinical trial assessing a study drug

Treatment and study plan

Lisinopril

Drug

5-10 mg Lisinopril per day for seven days, depending on blood pressure.

Other names: ACE inhibitor

Placebo

Drug

Matched placebo; identical tablets to Lisinopril.

Other names: Dummy drug

Primary outcomes

  1. Number of participants enrolled per month

    Time frame: 1 year

    The primary outcome measure is the number of participants enrolled in the study per month.

Secondary outcomes

  1. Proportion fulfilling eligibility criteria

    Time frame: 1 year

    The proportion of suspected acute stroke patients admitted to research sites during the trial duration who fulfilled the study eligibility criteria

  2. Proportion attended by research trained paramedic

    Time frame: 1 year

    The proportion of study eligible patients attended by a research trained paramedic

  3. Proportion enrolled by research trained paramedic

    Time frame: 1 year

    The proportion of study eligible patients enrolled into the study by a researc trained paramedic

  4. Proportion approached but not enrolled

    Time frame: 1 year

    The proportion of study eligible patients approached about the research study but not enrolled, and the reasons for non-enrolment, where possible.

  5. Additional time spent on scene

    Time frame: 1 year

    The additional time spent on scene by research trained paramedics to enrol a participant into the study.

  6. Paramedic compliance

    Time frame: 1 year

    Paramedic compliance with study data collection.

  7. Hospital staff compliance

    Time frame: 1 year

    Hospital staff compliance with study medication administration and data collection.

  8. Proportion completing study medication

    Time frame: 1 year

    The proportion of study participants with confirmed stroke who complete seven days of study medication.

  9. Clinical outcome measures

    Time frame: 1 year

    Clinical outcome measures are blood pressure, neurological score, dependency score and renal function.

  10. Adverse events

    Time frame: 1 year

    Adverse events in control and intervention groups during the study.

Sponsors and collaborators

Lead sponsor

Newcastle-upon-Tyne Hospitals NHS Trust

Other

Collaborators

  • North East Ambulance Service NHS Foundation Trust
  • Northumbria Healthcare NHS Foundation Trust

Registry information

Official study title

Paramedic Initiated Lisinopril For Acute Stroke Treatment: a Pilot Randomised Controlled Trial

Acronym: PIL-FAST

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Feb 10, 2010
Registry last updated
Mar 30, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.